Biocryst Pharmaceuticals (BCRX) Amortizatization of Intangibles (2023 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Amortizatization of Intangibles of $251000.0 for Q1 2026, up 123.01% on a QoQ basis from -$1.1 million in Q4 2025, and up 118.15% year-over-year from $115059.0 in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Amortizatization of Intangibles history runs 4 years deep, the most recent figure standing at $251000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles rose 118.15% year-over-year to $251000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.7 million (up 72.12% YoY) and the FY2025 annual result came in at -$4.3 million, up 62.25% from the prior year.
- Amortizatization of Intangibles was $251000.0 for Q1 2026 at Biocryst Pharmaceuticals, up from -$1.1 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $251000.0 in Q1 2026 and bottomed at -$3.5 million in Q2 2024.
- A 4-year average of -$2.0 million and a median of -$2.0 million in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles tumbled 129.68% — and 2026, when it soared 118.15%.
- Biocryst Pharmaceuticals' Amortizatization of Intangibles stood at -$3.4 million in 2023, then increased by 19.98% to -$2.8 million in 2024, then jumped by 60.47% to -$1.1 million in 2025, then soared by 123.01% to $251000.0 in 2026.
- Business Quant data shows BCRX's Amortizatization of Intangibles at $251000.0 in Q1 2026, -$1.1 million in Q4 2025, and -$707000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.35 Bn | 2.28 Bn | 151.04 Mn | 251,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251,000.00 |
| Mar 31, 2026 | 251,000.00 |
| Dec 31, 2025 | -1.09 Mn |
| Dec 31, 2025 | -1.09 Mn |
| Sep 30, 2025 | -707,000.00 |
| Sep 30, 2025 | -707,000.00 |
| Jun 30, 2025 | -1.15 Mn |
| Jun 30, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Dec 31, 2024 | -2.76 Mn |
| Dec 31, 2024 | -2.76 Mn |
| Sep 30, 2024 | -2.04 Mn |
| Sep 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -3.49 Mn |
| Jun 30, 2024 | -3.49 Mn |
| Mar 31, 2024 | -3.18 Mn |
| Mar 31, 2024 | -3.18 Mn |
| Dec 31, 2023 | -3.45 Mn |
| Dec 31, 2023 | -3.45 Mn |